Treatment Effi cacy of Targeted Therapies for Metastatic Renal Cell Carcinoma—A Review
after Seven Years of Experience
28
with Metastatic Renal Cell Carcinoma (AVOREN): Final
Analysis of Overall Survival,” Journal of Clinical On-
cology, Vol. 28, No. 13, 2010, pp. 2144-2150.
http://dx.doi.org/10.1200/JCO.2009.26.7849
[14] B. I. Rini, S. Halabi, J. E. Rosenberg, et al., “Bevacizu-
mab plus Interferon Alfa Compared with Interferon Alfa
Monotherapy in Patients with Metastatic Renal Cell Car-
cinoma: CALGB 90206,” Journal of Clinical Oncology,
Vol. 26, No. 33, 2008, pp. 5422-5428.
http://dx.doi.org/10.1200/JCO.2008.16.9847
[15] B. I. Rini, S. Halabi, J. E. Rosenberg, et al., “Phase III
Trial of Bevacizumab plus Interferon Alfa versus Inter-
feron Alfa Monotherapy in Patients with Metastatic Renal
Cell Carcinoma: Final Results of CALGB 90206,” Jour-
nal of Clinical Oncology, Vol. 28, No. 13, 2010, pp.
2137-2143. http://dx.doi.org/10.1200/JCO.2009.26.5561
[16] G. Hudes, M. Carducci, P. Tomczak, et al., “Temsiroli-
mus, Interferon Alfa, or Both for Advanced Renal-Cell
Carcinoma,” The New England Journal of Medicine, Vol.
356, 2007, pp. 2271-2281.
http://dx.doi.org/10.1056/NEJMoa066838
[17] R. J. Motzer, B. Escudier, S. Oudard, et al., “Efficacy of
Everolimus in Advanced Renal Cell Carcinoma: A Dou-
ble-Blind, Randomised, Placebo-Controlled Phase III Tri a l, ”
Lancet, Vol. 372, No. 9637, 2008, pp. 449-456.
http://dx.doi.org/10.1016/S0140-6736(08)61039-9
[18] R. J. Motzer, B. Escudier, S. Oudard, et al., “Phase 3
Trial of Everolimus for Met astatic Re nal Cell Carcinoma :
Final Results and Analysis of Prognostic Factors,” Can-
cer, Vol. 116, No. 18, 2010, pp. 4256-4265.
http://dx.doi.org/10.1002/cncr.25219
[19] C. N. Sternberg, I. D. Davis, J. Mardiak, et al., “Pazo-
panib in Locally Advanced or Metastatic Renal Cell Car-
cinoma: Results of a Randomized Phase III Trial,” Jour-
nal of Clinical Oncology, Vol. 28, No. 6, 2010, pp. 1061-
1068. http://dx.doi.org/10.1200/JCO.2009.23.9764
[20] C. N. Sternberg, R. E. Hawkins, J. Wagstaff, et al., “A
Randomised, Double-Blind Phase III Study of Pazopanib
in Patients with Advanced and/or Metastatic Renal Cell
Carcinoma: Final Overall Survival Results and Safety
Update,” European Journal of Cancer, Vol. 49, No. 6,
2013, pp. 1287-1296.
http://dx.doi.org/10.1016/j.ejca.2012.12.010
[21] R. Motzer, T. E. Hutson and J. Reeves, “Randomized,
Open Label, Phase III Trial of Pazopanib versus Sunitinib
in First-Line Treatment of Patients with Metastatic Renal
Cell Carcinoma (mRCC): Results of the COMPARZ
Trial,” Annals of Oncology, Vol. 23, 2012, Article ID:
LBA8.
[22] B. I. Rini, B. Escudier, P. Tomczak, et al., “Comparative
Effectiveness of Axitinib versus Sorafenib in Advanced
Renal Cell Carcinoma (AXIS): A Randomised Phase 3
Trial,” Lancet, Vol. 378, No. 9807, 2011, pp. 1931-1939.
http://dx.doi.org/10.1016/S0140-6736(11)61613-9
[23] R. Motzer, B. Escudier and P. Tomczak, “Axitinib vs
Sorafenib for Advanced Renal Cell Carcinoma: Phase III
Overall Survival Results and Analysis of Prognostic Fac-
tors,” Annals of Oncology, Vol. 23, 2012.
[24] R. J. Motzer, B. Escudier, P. Tomczak, et al., “Axitinib
versus Sorafenib as Second-Line Treatment for Advanced
Renal Cell Carcinoma: Overall Survival Analysis and Up-
dated Results from a Randomised Phase 3 Trial,” Lancet
Oncology, Vol. 14, No. 6, 2013, pp. 552-562.
http://dx.doi.org/10.1016/S1470-2045(13)70093-7
[25] R. J. Motzer, T. E. Hutson, M. R. Olsen, et al., “Ran-
domized Phase II Trial of Sunitinib on an Intermittent
versus Continuous Dosing Schedule as First-Line Ther-
apy for Advanced Renal Cell Carcinoma,” Journal of
Clinical Oncology, Vol. 30, No. 12, 2012, pp. 1371-1377.
http://dx.doi.org/10.1200/JCO.2011.36.4133
[26] B. Rini, C. Szczylik, N. M. Tannir, et al., “AMG 386 in
Combination with Sorafenib in Patients with Metastatic
Clear Cell Carcinoma of the Kidney: A Randomized,
Double-Blind, Placebo-Controlled, Phase 2 Study,” Can-
cer, Vol. 118, No. 24, 2012, pp. 6152-6161.
http://dx.doi.org/10.1002/cncr.27632
[27] R. Motzer, D. Nosov and T. Eisen, “Tivozanib versus
Sorafenib as Initial Targeted Therapy for Patients with
Advanced Renal Cell Carcinoma: Results from a Phase
III Randomized, Open-Label, Multicenter Trial,” Journal
of Clinical Oncology, Vol. 30, 2012.
[28] T. E. Hutson, D. Nosov and T. Eisen, “Subgroup Analy-
ses of a Phase III Trial Comparing Tivozanib Hydrochlo-
ride versus Sorafenib as Initial Targeted Therapy for Pa-
tients (pts) with Metastatic Renal Cell Carcinoma (mRCC),”
Journal of Clinical Oncology, Vol. 31, 2013.
[29] R. Motzer, T. Eisen and T. E. Hutson, “Overall Survival
Results from a Phase III Study of Tivozanib Hydrochlo-
ride versus Sorafenib in Patients with Renal Cell Carci-
noma,” Journal of Clinical Oncology, Vol. 31, 2013.
[30] T. E. Hutson, J. Gallardo and V. Lesovoy, “Axitinib ver-
sus Sorafenib as First-Line Therapy in Patients with Me-
tastatic Renal Cell Carcinoma (mRCC),” Journal of Cli-
nical Oncology, Vol. 31, 2013.
[31] B. Rini, J. Bellmunt and J. Clancy, “Randomized Phase
IIIb Trial of Temsirolimus and Bevacizumab versus In-
terferon and Bevacizumab in Metastatic Renal Cell Car-
cinoma: Results from INTORACT,” ESMO, 2012, Article
ID: LBA1487.
[32] T. E. Hutson, B. Escudier and E. Esteban, “Temsirolimus
vs Sorafenib as Second Line Therapy in Metastatic Renal
Cell Carcinoma: Results from the INTORSECT Trial,”
Annals of Oncology, Vol. 23, 2012, Article ID: LBA22.
[33] B. Escudier, C. Szczylik, T. E. Hutson, et al., “Random-
ized Phase II Trial of First-Line Treatment with Sorafenib
versus Interferon Alfa-2a in Patients with Metastatic Re-
nal Cell Carcinoma,” Journal of Clinical Oncology, Vol.
27, No. 8, 2009, pp. 1280-1289.
http://dx.doi.org/10.1200/JCO.2008.19.3342
[34] G. Procopio, E. Verzoni and F. de Braud, “Targeted The-
rapies and Survival: What We Can Learn from Studies in
Advanced Renal Cell Carcinoma,” Oncology, Vol. 84, No.
1, 2013, pp. 39-42. http://dx.doi.org/10.1159/000342768
[35] M. P. Sablin, S. Negrier, A. Ravaud, et al., “Sequential
Sorafenib and Sunitinib for Renal Cell Carcinoma,” Jour-
nal of Urology, Vol. 182, 2009, pp. 29-34.
http://dx.doi.org/10.1016/j.juro.2009.02.119
Copyright © 2013 SciRes. JCT